UK News Archive

The UK News Archive contains resources intended for journalists only.

2021

February

Media Release / Feb 26, 2021

Novartis’ Kisqali® (ribociclib) receives NICE recommendation for routine funding as second-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer

Read More
Media Release / Feb 17, 2021

Maintain COVID-19 collaborations to secure UK’s life sciences lead, recommends new report

Read More
Media Release / Feb 12, 2021

Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

Read More
Media Release / Feb 03, 2021

NICE issues final guidance recommending Novartis’ novel eye treatment Beovu® (brolucizumab) as an option for wet age-related macular degeneration

Read More

January

Media Release / Jan 29, 2021

Novartis receives positive CHMP opinion for Kesimpta® (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis with active disease

Read More
Story / Jan 29, 2021

Novartis UK awarded Top Employer status for eighth consecutive year

Read More
Media Release / Jan 25, 2021

Novartis UK Estradot supplies statement

Read More
2020

December

Media Release / Dec 11, 2020

Aimovig® (erenumab) NICE Final Appraisal Document (FAD) publication – Novartis UK media statement

Read More

November

Story / Nov 17, 2020

Novartis walks-the-talk with the Red Shoe Movement

Read More

October

Media Release / Oct 15, 2020

Novartis’ Mayzent®▼ (siponimod) becomes the first oral treatment recommended by NICE and SMC for adults living with secondary progressive multiple sclerosis (SPMS) with active disease

Read More

Related Links